• Samah Elsaadi
  • Kristine Misund
  • Pegah Abdollahi
  • Esten Nymoen Vandsemb
  • Siv Helen Moen
  • Anna Kusnierczyk
  • Geir Slupphaug
  • Therese Standal
  • Anders Waage
  • Tobias S Slørdahl
  • Torstein Baade Rø
  • Even Rustad
  • Anders Sundan
  • Carl Hay
  • Zachary Cooper
  • Alwin G Schuller
  • Richard Woessner
  • Alexandra Borodovsky
  • Magne Børset
  • Anne Marit Sponaas

BACKGROUND: PD1/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and its immunosuppressive receptor should be considered. CD39 and CD73 convert extracellular ATP to adenosine, which inhibits T-cell effector functions via the adenosine receptor A2A (A2AR). We set out to investigate whether blocking the adenosine pathway could be a therapy for MM.

METHODS: Expression of CD39 and CD73 on BM cells from patients and T-cell proliferation were determined by flow cytometry and adenosine production by Liquid chromatograpy-mass spectrometry (HPCL/MS). ENTPD1 (CD39) mRNA expression was determined on myeloma cells from patients enrolled in the publicly available CoMMpass study. Transplantable 5T33MM myeloma cells were used to determine the effect of inhibiting CD39, CD73 and A2AR in mice in vivo.

RESULTS: Elevated level of adenosine was found in BM plasma of MM patients. Myeloma cells from patients expressed CD39, and high gene expression indicated reduced survival. CD73 was found on leukocytes and stromal cells in the BM. A CD39 inhibitor, POM-1, and an anti-CD73 antibody inhibited adenosine production and reduced T-cell suppression in vitro in coculture of myeloma and stromal cells. Blocking the adenosine pathway in vivo with a combination of Sodium polyoxotungstate (POM-1), anti-CD73, and the A2AR antagonist AZD4635 activated immune cells, increased interferon gamma production, and reduced the tumor load in a murine model of MM.

CONCLUSIONS: Our data suggest that the adenosine pathway can be successfully targeted in MM and blocking this pathway could be an alternative to PD1/PDL1 inhibition for MM and other hematological cancers. Inhibitors of the adenosine pathway are available. Some are in clinical trials and they could thus reach MM patients fairly rapidly.

Original languageEnglish
Article numbere000610
Number of pages14
JournalJournal for immunotherapy of cancer
Issue number1
Publication statusPublished - 2020

    Research areas

  • adenosine, hematologic neoplasms, immunotherapy, tumor microenvironment

ID: 52150241